EU AI Act overlap with MDR/IVDR for medical AI and SaMD
Key Questions
What delays are introduced by the early-2026 EU AI Act amendments?
High-risk AI systems under the AI Act are delayed to December 2027 or August 2028, with specific relief for medical devices. This provides additional time for compliance with overlapping regulations.
What are the key overlaps between the EU AI Act and MDR/IVDR?
Overlaps include data requirements, Post-Market Surveillance (PMS), and transparency obligations for medical AI and Software as a Medical Device (SaMD). Manufacturers should map obligations and align documentation, PMS, and technical audits.
What guidance exists for human factors in AI/ML-enabled devices?
Jonathan Kendler's work, including AEGIS/HFE checklists, addresses rethinking human factors engineering for AI/ML devices, highlighting risks noted in NEJM. This is crucial amid MHRA DMHT drift and usability concerns.
What cybersecurity and labeling considerations are relevant?
German Notified Body (NB) guidance covers cybersecurity for AI devices. Apple labeling requirements are set for 2027, alongside evidence needs for AI Medical Diagnostic Devices (AIMDD).
How should companies prepare for AI Act and MDR/IVDR compliance?
Align documents, PMS, and conduct tech audits to address overlaps. Utilize resources like clinical evidence requirements for AIMDD and researcher guidance for safer AI-enabled medical devices.
Early-2026 amendments delay high-risk AI Act to Dec 2027/Aug 2028 with med device relief; overlaps data/PMS/transparency. MHRA DMHT drift/usability; German NB cyber; AEGIS/HFE checklists (Kendler/NEJM risks); Apple labeling (2027); AIMDD evidence. Map obligations, align docs/PMS/tech audits.